ProUroCare Medical, Inc. engages in the development of products for the detection and characterization of male prostate disease. The company is headquartered in Eden Prairie, Minnesota and currently employs 2 full-time employees. The company went IPO on 2002-05-28. The firm is focused on its product, a prostate mechanical imaging device called the ProUroScan System. The ProUroScan is an advanced medical imaging system that uses an array of sensors mounted on a rectal probe, a central processing unit and software and image construction algorithms to provide a real time color image of abnormalities in the prostate. The ProUroScan System probe is specially designed for the rectal anatomy to minimize patient discomfort. In addition, it provides mechanical or elasticity imaging, which refers to a non-invasive analysis of tissue movement and displacement. The ProUroScan technique works by computing how tissue moves in response to pressure, thus evaluating its softness or stiffness. Its product also provides two-and three-dimensional prostate images.
Follow-Up Questions
PUMD 주식의 가격 성능은 어떻습니까?
PUMD의 현재 가격은 $0.0002이며, 전 거래일에 decreased 0% 하였습니다.
ProUroCare Medical Inc의 주요 사업 주제나 업종은 무엇입니까?
ProUroCare Medical Inc은 N/A 업종에 속하며, 해당 부문은 N/A입니다